Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
High growth potential established dividend payer.
Share Price & News
How has Bristol-Myers Squibb's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BMY has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: BMY exceeded the US Pharmaceuticals industry which returned 6.7% over the past year.
Return vs Market: BMY exceeded the US Market which returned 20.3% over the past year.
Price Volatility Vs. Market
How volatile is Bristol-Myers Squibb's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StBristol-Myers Squibb Company Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
2 weeks ago | Simply Wall StBristol-Myers Squibb (NYSE:BMY) Seems To Use Debt Rather Sparingly
1 month ago | Simply Wall StHow Should Investors Feel About Bristol-Myers Squibb Company's (NYSE:BMY) CEO Pay?
Is Bristol-Myers Squibb undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BMY ($65.71) is trading below our estimate of fair value ($189.05)
Significantly Below Fair Value: BMY is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BMY is poor value based on its PE Ratio (32.6x) compared to the Pharmaceuticals industry average (21.5x).
PE vs Market: BMY is poor value based on its PE Ratio (32.6x) compared to the US market (18.3x).
Price to Earnings Growth Ratio
PEG Ratio: BMY is good value based on its PEG Ratio (0.4x)
Price to Book Ratio
PB vs Industry: BMY is overvalued based on its PB Ratio (6.1x) compared to the US Pharmaceuticals industry average (3.1x).
How is Bristol-Myers Squibb forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BMY's forecast earnings growth (82.4% per year) is above the savings rate (1.7%).
Earnings vs Market: BMY's earnings (82.4% per year) are forecast to grow faster than the US market (14.2% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: BMY's revenue (8.1% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: BMY's revenue (8.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BMY's Return on Equity is forecast to be high in 3 years time (25.4%)
How has Bristol-Myers Squibb performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BMY has a high level of non-cash earnings.
Growing Profit Margin: BMY's current net profit margins (13.2%) are lower than last year (21.8%).
Past Earnings Growth Analysis
Earnings Trend: BMY's earnings have grown by 16.7% per year over the past 5 years.
Accelerating Growth: BMY's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BMY had negative earnings growth (-30.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (2.4%).
Return on Equity
High ROE: BMY's Return on Equity (19.5%) is considered low.
Return on Assets
Return on Capital Employed
How is Bristol-Myers Squibb's financial position?
Financial Position Analysis
Short Term Liabilities: BMY's short term assets ($40.2B) exceed its short term liabilities ($10.5B).
Long Term Liabilities: BMY's short term assets ($40.2B) exceed its long term liabilities ($29.2B).
Debt to Equity History and Analysis
Debt Level: BMY's debt to equity ratio (141.9%) is considered high.
Reducing Debt: BMY's debt to equity ratio has increased from 52.2% to 141.9% over the past 5 years.
Debt Coverage: BMY's debt is well covered by operating cash flow (33.6%).
Interest Coverage: BMY's interest payments on its debt are well covered by EBIT (37x coverage).
Inventory Level: BMY has a low level of unsold assets or inventory.
Debt Coverage by Assets: BMY's debt is covered by short term assets (assets are 1.6x debt).
What is Bristol-Myers Squibb's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: BMY's dividend (2.74%) is higher than the bottom 25% of dividend payers in the US market (1.44%).
High Dividend: BMY's dividend (2.74%) is low compared to the top 25% of dividend payers in the US market (3.73%).
Stability and Growth of Payments
Stable Dividend: BMY's dividends per share have been stable in the past 10 years.
Growing Dividend: BMY's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: At its current payout ratio (83.3%), BMY's payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: BMY's dividends in 3 years are forecast to be well covered by earnings (25.7% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Giovanni Caforio (54yo)
Dr. Giovanni Caforio, M.D. serves as the Chief Executive Officer at Bristol-Myers Squibb Belgium NV/SA. Dr. Caforio has been the Chief Executive Officer of Bristol-Myers Squibb Farmacêutica Portuguesa, SA ...
CEO Compensation Analysis
Compensation vs Market: Giovanni's total compensation ($USD19.38M) is above average for companies of similar size in the US market ($USD10.78M).
Compensation vs Earnings: Giovanni's compensation has been consistent with company performance over the past year.
|Chairman of the Board & CEO||4.8yrs||US$19.38m||0.016% $24.5m|
|Executive VP & General Counsel||13yrs||US$6.24m||0.025% $36.5m|
|Executive VP & Head of Integration||0.2yrs||US$7.89m||0.017% $25.9m|
|Executive VP and President of Global Product Development & Supply||2.8yrs||US$4.13m||0.0014% $2.1m|
|Executive VP & CFO||0.3yrs||no data||0.00091% $1.4m|
|Executive VP & Chief Information Officer||8.1yrs||no data||0.0060% $8.9m|
|Executive Vice President of Investor Relations||3.1yrs||no data||0.0033% $4.9m|
|Senior VP & Chief Compliance and Ethics Officer||2.1yrs||no data||0.00074% $1.1m|
|Executive VP & Chief Human Resources Officer||3.7yrs||no data||0.0014% $2.1m|
|Head of US Drug Makers - India||5.6yrs||no data||no data|
Experienced Management: BMY's management team is considered experienced (3.4 years average tenure).
|Chairman of the Board & CEO||4.8yrs||US$19.38m||0.016% $24.5m|
|Independent Director||8.1yrs||US$325.00k||no data|
|Independent Director||12.1yrs||US$340.81k||0.00010% $148.7k|
|Lead Independent Director||2.8yrs||US$388.31k||no data|
|Independent Director||12.9yrs||US$355.00k||0.00015% $223.1k|
|Independent Director||6.6yrs||US$307.50k||0.00057% $847.7k|
|Independent Director||3yrs||US$345.00k||0.000010% $14.9k|
|Independent Director||3yrs||US$324.16k||0.00051% $758.5k|
|Independent Director||3.8yrs||US$332.75k||no data|
|Independent Director||3yrs||US$337.50k||0.0012% $1.8m|
Experienced Board: BMY's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BMY insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.4%.
Bristol-Myers Squibb Company's company bio, employee growth, exchange listings and data sources
- Name: Bristol-Myers Squibb Company
- Ticker: BMY
- Exchange: NYSE
- Founded: 1887
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$148.724b
- Shares outstanding: 2.25b
- Website: https://www.bms.com
Number of Employees
- Bristol-Myers Squibb Company
- 430 East 29th Street
- 14th Floor
- New York
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BMY||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Jan 1968|
|BMY *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Jan 1968|
|BRM||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 1968|
|BRM||XTRA (XETRA Trading Platform)||Yes||Common Stock||DE||EUR||Jan 1968|
|BMY||SWX (SIX Swiss Exchange)||Yes||Common Stock||CH||CHF||Jan 1968|
|0R1F||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jan 1968|
|BRM||ETLX (Eurotlx)||Yes||Common Stock||IT||EUR||Jan 1968|
|BMYS||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||Jan 1968|
|BMY||BASE (Buenos Aires Stock Exchange)||CEDEAR EACH REP 1 COM USD0.10||AR||ARS||Mar 2009|
|BMYB34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EA REPR 1 COM SHS||BR||BRL||Aug 2012|
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company’s products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. Bristol-Myers Squibb Company has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; FameWave Ltd.; Novartis; Presage Biosciences; and WindMIL Therapeutics, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/19 23:44|
|End of Day Share Price||2020/02/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.